“Global next-generation sequencing (NGS) Services market is anticipated to reach USD 6.49 billion by 2030”, says Visiongain

29 November 2019

Visiongain has launched a new pharma report ‘’Next-Generation Sequencing (NGS) Services Market Report’’ by Service Type (Human Genome Sequencing Services, Single Cell Sequencing Services, Microbial Genome - based Sequencing Services, Animal & Plant Sequencing, Gene Regulation Services (Small RNA sequencing service, ChIP sequencing, Other gene regulation - based service), Other Sequencing Services), Workflow (Data Analysis Service, Pre Sequencing Service, Sequencing Service), End Users (Hospitals & Clinics, Pharma & Biotech, Universities & Other Research Facilities, Other End Users), and Geography.

The global next-generation sequencing (NGS) Services market is anticipated to grow at a lucrative CAGR of 13.8% and anticipated to reach USD 6.49 billion by 2030.

In terms of reproducibility and cost savings, the advancement of NGS technology has revolutionized gene sequencing. As a result, many developments in NGS technology have been made to facilitate its use in medical laboratories and hospitals. Most of the current innovations in the NGS industry spin around the simplification & sophistication in the usage of seq-technology. Such factors have motivated several end-users to take up NGS services.

Service providers of traditional disease testing have increased their scope with an increasing trend in sequential genetic testing. For instance, ARUP Laboratories collaborated with the CHOP (Children's Hospital of Philadelphia) in October 2014. In November 2017, service provision for HLA genotyping based on NGS, including HLA Class I & II, began.

With the rising trend of high-performance sequencing in the pharmaceutical and biotech industries, further innovations are needed to improve the speed and convenience of seq-platforms with high-performance and simplify workflows. As a result, companies are focusing on developing approaches to improve sample amplification and purification.

The new Small RNA Library Prep Kit for Illumina was launched by Norgen in July 2017. This kit is being designed to produce small RNA libraries and is configured for low-input RNA (0.5-1ng) samples such as urine, saliva, plasma, blood, and exosomes.

Data generated by genome sequencing is considered as an important diagnostic method which enables clinicians to identify specific characteristics in the patient, thus helping clinicians with tailored treatments, thus increasing clinical results. In the coming years, this aspect is expected to fuel demand for NGS-based diagnostics.

However, some of the major issues faced by customers while conducting single-cell seq are introducing large-scale data analysis and analytical problems. Nonetheless, manufacturers are actively investing in research & development to tackle these obstacles and increase the scope of next-generation sequencing services.

On the other hand, during the forecast period, gene regulatory services were expected to show a lucrative CAGR. This includes small sequencing of RNA, ChIP-sequencing, sequencing of lncRNA, isoform sequencing and sequencing of bisulfite. In many applications, numerous advantages provided by RNA sequencing have allowed microarrays to be replaced. The application of RNA-seq is expected to continue to expand in the coming years, driving rapid growth in the field.

Researchers engaged in performing sequencing protocols for their projects face great challenges in analyzing NGS results. This is because of the effective collection and interpretation of data requires a structured and knowledgeable methodology. As the number of sequenced reads per run increases, there is expected a resulting increase in demand for a reliable data management solution.

In the year 2018, North America dominated the global next-generation sequencing market owing to factors such as well-established computer networks, successful regulatory guidelines for genetic testing acceptance and use, and the presence of major players in the region. Also, increasing numbers of genomic tests approved by the FDA in the U.S. are expected to drive the regional market throughout the forecast period.

The Asia Pacific next-generation sequencing market is anticipated to grow at a lucrative CAGR over the forecast period owing to growing government investments in the development of advanced diagnostic approaches. Also, domestic players in Asian countries are involved in establishing mutually beneficial alliances for the establishment of NGS service providers, as well as with global companies. For example, Novogene (China) partnered with AITbiotech based in Singapore in 2017 to set up NovogeneAIT Genomics Singapore Pte Ltd. to provide next-generation sequencing services across Southeast Asian countries.

Currently, key players are forming various strategies such as acquisitions, mergers, partnerships, collaborations and launching new products to strengthen their position in the global next-generation sequencing (NGS) market. Companies are also expanding their R&D, distribution, and management facilities to expand their business and to hold a competitive edge in the NGS Services market.

The comprehensive market report features companies such as Abm Inc., ARUP Laboratories, BGI, Gene by Gene, GENEWIZ Germany GmbH, Illumina, Inc., Lucigen, NanoString Technologies, Inc., Novogene Corporation, Pacific Biosciences of California, Inc., Quest Diagnostics, Veritas Genetics, SeqLL Inc., CD Genomics, Otogenetics Corporation, DNA Link, Inc., MedGenome Inc., SciGenom Labs Pvt. Ltd, PerkinElmer, Inc., Qiagen N.V. among other prominent players. Also the research study offers market estimation and forecast for the period ranging 2020-2030 for global markets such as North America, Latin America, Europe, Asia Pacific and MEA along with regional sub-markets as U.S., Canada, Brazil, Mexico, Germany, UK, France, Italy, Spain, Russia, India, Japan, China, Australia, ASEAN, GCC and South Africa.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021


Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021


Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021


Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021